Novo Integrated Sciences (Novo Integrated Sciences) EPS (Diluted) : $-0.64 (TTM As of Feb. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Novo Integrated Sciences EPS (Diluted)?

Novo Integrated Sciences's Earnings per Share (Diluted) for the three months ended in Feb. 2024 was $-0.16. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2024 was $-0.64.

Novo Integrated Sciences's EPS (Basic) for the three months ended in Feb. 2024 was $-0.16. Its EPS (Basic) for the trailing twelve months (TTM) ended in Feb. 2024 was $-0.64.

Novo Integrated Sciences's EPS without NRI for the three months ended in Feb. 2024 was $-0.18. Its EPS without NRI for the trailing twelve months (TTM) ended in Feb. 2024 was $-0.68.

During the past 3 years, the average EPS without NRIGrowth Rate was 12.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was -35.60% per year. During the past 10 years, the average EPS without NRI Growth Rate was 14.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Novo Integrated Sciences's highest 3-Year average EPS without NRI Growth Rate was 62.00% per year. The lowest was -188.10% per year. And the median was 27.90% per year.

Novo Integrated Sciences EPS (Diluted) Historical Data

The historical data trend for Novo Integrated Sciences's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Integrated Sciences EPS (Diluted) Chart

Novo Integrated Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

EPS (Diluted)

Get a 7-Day Free Trial

-0.18

-2.10

-1.80

-11.28

-1.30

Novo Integrated Sciences Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
EPS (Diluted)	Get a 7-Day Free Trial															-0.59	-0.10	-0.10	-0.28	-0.16

Competitive Comparison of Novo Integrated Sciences's EPS (Diluted)

For the Medical Care Facilities subindustry, Novo Integrated Sciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novo Integrated Sciences's PE Ratio Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Novo Integrated Sciences's PE Ratio distribution charts can be found below:

* The bar in red indicates where Novo Integrated Sciences's PE Ratio falls into.

Novo Integrated Sciences EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Novo Integrated Sciences's Diluted EPS for the fiscal year that ended in Aug. 2023 is calculated as

Diluted EPS (A: Aug. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-13.215	-	0)	/	10.166
	=	-1.30

Novo Integrated Sciences's Diluted EPS for the quarter that ended in Feb. 2024 is calculated as

Diluted EPS (Q: Feb. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-2.746	-	0)	/	17.643
	=	-0.16

EPS (Diluted) for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.64

Novo Integrated Sciences (NAS:NVOS) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Novo Integrated Sciences EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Novo Integrated Sciences's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Integrated Sciences (Novo Integrated Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Novo Integrated Sciences Inc (NAS:NVOS) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

11120 NE 2nd Street, Suite 100, Bellevue, WA, USA, 98004

Website

https://www.novointegrated.com

Novo Integrated Sciences Inc is a medical care company. It provides specialized physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, massage therapy, acupuncture, neurological functions, kinesiology, and others. It has two reportable segments: healthcare services which generates majority of the revenue, and product sales.

Executives

Sarfaraz Ali	director	C/O NOVO INTEGRATED SCIENCES, INC.,, 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004
Robert Letterio Oliva	director	115 BELFIELD RD, TORONTO A6 L0J 1C0
Sterling M. Jimenez	officer: Principal Financial Officer	C/O NOVO INTEGRATED SCIENCES, INC.,, 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004
Michael Ross Pope	director	1045 PROGRESS CIRCLE, LAWRENCEVILLE, GEORGIA GA 30043
Alex Flesias	director	41 LANDMARK COURT, UNIONVILLE A6 L3R 9N7
Michael Joseph Gaynor	director	49 BALMORAL ST, KEMPTVILLE A6 K0G 1J0
Robert Mattacchione	director, 10 percent owner, officer: Chief Executive Officer	79 SELVAPIANO CRES, WOODBRIDGE A6 L4H 0X1
Pierre Joseph Dalcourt	director, 10 percent owner	35 BRYANT ST , BOX 2230, HEARST A6 P0L 1N0
Christopher Mehlin David	director, officer: President	10425 SE 22ND ST., BELLEVUE WA 98004
Thomas Edward Bray	officer: Principal Financial Officer	C/O NOVO INTEGRATED SCIENCES, INC., 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004
Rebecca Aw Mcdonald	officer: Chief Accounting Officer	1301 INTERNATIONAL SPEEDWAY BLVD., DELAND FL 32724
James Jr Teters	director	1200 FLIGHTLINE BLVD, STE 5, DELAN FL 32724
Phyllis Rouse	officer: secretary	1200 FLIGHLINE BLVD,, SUITE 5, DELAND FL 32724
Jay Hilden	officer: President & CEO	1200 FLIGHLINE BLVD,, SUITE 5, DELAND FL 32724
Robert Adamo	director	1200 FLIGHTLINE BOULEVARD, SUITE 5, DELAND FL 32724